Injectable division
CagriSema
AClass-leading
Novo Nordisk · certified
vs
Injectable division
Retatrutide
Class-leadingA
Eli Lilly · certified
17%
Efficacy
a hair ahead · 21%
Mild (+2.3) · gentler
Tolerability
Notable (+6.4)
Subcutaneous injection
Route
Subcutaneous injection
None
Food / water rule
None
Refrigerated
Storage
Refrigerated
The call: On efficacy they are effectively tied, both class leading, with Retatrutide's 21% a hair ahead of 17%, a gap the tiers are built to absorb. CagriSema is the easier of the two to stay on (Mild vs Notable). One caveat: Retatrutide's number is topline, not yet peer-reviewed and not yet approved, while CagriSema's is published, so read even the narrow edge as provisional.
Standalone, this page carries its own key: Efficacy = % body weight lost vs placebo, on the conservative estimand that counts everyone. Tolerability = AE-discontinuation over placebo (Mild 1 to 5 · Notable 5 to 10 · Heavy over 10 points). Winners are called only across a tier or band boundary; within one, the drugs are effectively tied. The side marked leads or gentler wins that axis.
CagriSema verdict · Retatrutide verdict · How this is scored